0000000000118057
AUTHOR
Elena Cortés-vicente
Clinical characteristics and outcomes of thymoma-associated myasthenia gravis
[Background and purpose] Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.
The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis
ObjectiveTo evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. MethodsThis retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. ResultsTwenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m(2)/4 w…
Clinical and therapeutic features of myasthenia gravis in adults based on age at onset
[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).